Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025

Go back to Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025
AdvanSource Biomaterials Corpration (AMEX: ASNB) Delayed: 0.85 --0 (-0%)
Previous Close $0.85    52 Week High $0.41 
Open $7.87    52 Week Low $0.05 
Day High $0.85    P/E N/A 
Day Low $0.85    EPS $-0.12 
Volume 80       

NORD ANGLIA EDUCATION, Inc. (AMEX: NORD) Delayed: 3.50 -0.52 (12.94%)
Previous Close $4.02    52 Week High $23.88 
Open $3.60    52 Week Low $14.58 
Day High $3.60    P/E N/A 
Day Low $3.49    EPS $0.00 
Volume 8,185